Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Interim results for BCMA T-cell engager CC-93269 in RRMM

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, presents the interim results of the first clinical study of the bispecific BCMA/CD3 T-cell engager CC-93269 in patients with relapsed/refractory multiple myeloma (CC-93269-MM-001; NCT03486067). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.